Literature DB >> 9631140

Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.

P Kazanjian1, A B Locke, P A Hossler, B R Lane, M S Bartlett, J W Smith, M Cannon, S R Meshnick.   

Abstract

BACKGROUND: Failures of prophylaxis against Pneumocystis carinii pneumonia (PCP) in AIDS patients do occur, but no evidence for drug resistance has yet been presented.
OBJECTIVE: To determine whether mutations in the sulfa and sulfone drug target are associated with failure of prophylaxis using a sulfa-containing agent.
METHODS: Portions of the gene for P. carinii dihydropteroate synthase (DHPS), the sulfa and sulfone target, from 27 patients (20 of whom had AIDS) diagnosed with PCP between 1976 and 1997 were amplified using polymerase chain reaction and sequenced. Seven of the 27 patients (all of whom had AIDS) were receiving sulfa or sulfone drugs as prophylaxis for PCP.
RESULTS: Mutations were found at only two amino-acid positions and were significantly more common in patients who received sulfa/sulfone prophylaxis. Mutations were observed in five (71%) out of seven isolates from AIDS patients receiving sulfa/sulfone as prophylaxis compared with only two (15%) out of 13 specimens from AIDS patients who did not (P = 0.022). No mutations were seen in isolates from seven non-HIV-infected patients, none of whom were on prophylaxis. Mutations were only observed in specimens obtained in 1995-1997.
CONCLUSIONS: Mutations in two amino-acid positions were significantly more common in AIDS patients with PCP who failed sulfa/sulfone prophylaxis. These amino acids appeared to be directly involved in both substrate and sulfa binding, based on homology to the Escherichia coli DHPS crystal structure. Thus, the results were consistent with the possibility that mutations in the P. carinii DHPS are responsible for some of the failures of sulfa/sulfone prophylaxis in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631140     DOI: 10.1097/00002030-199808000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

1.  Genetic analysis of multiple loci suggests that mutations in the Pneumocystis carinii f. sp. hominis dihydropteroate synthase gene arose independently in multiple strains.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.

Authors:  Melanie T Cushion; Peter D Walzer; Alan Ashbaugh; Sandra Rebholz; Ronald Brubaker; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.

Authors:  T Takahashi; N Hosoya; T Endo; T Nakamura; H Sakashita; K Kimura; K Ohnishi; Y Nakamura; A Iwamoto
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

4.  Rapid detection of mutations in the human-derived Pneumocystis carinii dihydropteroate synthase gene associated with sulfa resistance.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 5.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Dihydropteroate synthase and novel dihydrofolate reductase gene mutations in strains of Pneumocystis jirovecii from South Africa.

Authors:  F J L Robberts; L J Chalkley; K Weyer; P Goussard; L D Liebowitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission.

Authors:  C B Beard; J L Carter; S P Keely; L Huang; N J Pieniazek; I N Moura; J M Roberts; A W Hightower; M S Bens; A R Freeman; S Lee; J R Stringer; J S Duchin; C del Rio; D Rimland; R P Baughman; D A Levy; V J Dietz; P Simon; T R Navin
Journal:  Emerg Infect Dis       Date:  2000 May-Jun       Impact factor: 6.883

8.  Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort.

Authors:  Christina Yoon; Anuradha Subramanian; Amy Chi; Kristina Crothers; Steven R Meshnick; Steve M Taylor; Charles B Beard; Leah G Jarlsberg; Gena G Lawrence; Melissa Avery; Alexandra Swartzman; Serena Fong; Brenna Roth; Laurence Huang
Journal:  Med Mycol       Date:  2013-03-08       Impact factor: 4.076

9.  Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis.

Authors:  E Calderón; C de la Horra; F J Medrano; A López-Suárez; M A Montes-Cano; N Respaldiza; J Elvira-González; J Martín-Juan; A Bascuñana; J M Varela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-03       Impact factor: 3.267

Review 10.  A new name (Pneumocystis jiroveci) for Pneumocystis from humans.

Authors:  James R Stringer; Charles B Beard; Robert F Miller; Ann E Wakefield
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.